SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
LAVA Medtech Acquisition Corp. (LVACU) trades at a trailing P/E of 33.6. Trailing earnings yield is 2.98%.
Criteria proven by this page:
- VALUE (40/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Trailing Earnings Yield 2.98% — below bond yields — investors are paying a premium for expected growth rather than current earnings.
Overall SharesGrow Score: 44/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
40/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — LVACU
Valuation Multiples
P/E (TTM)33.6
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.31
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings Yield2.98%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2021 |
$1.25 |
$0.00 |
$17.97M |
- |
| 2022 |
$0.31 |
$0.00 |
$4.51M |
- |
